CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting

CS1001-201 study demonstrated an objective response rate (ORR) of 44.7%,a complete response (CR) rate of 31.6%,median overall survival (mOS) of 19.7 months and an one-year overall survival (OS) rate of 55.5% in patients with relapsed or refractory extranodal natural killer /T cell lymphoma (R/R ENKTL) treated with sugemalimab

CS1001-101 study demonstrated an ORR of 62.1%,median progression-free survival (mPFS) of 8.3 months and mOS of 17.0 months in patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (GC/GEJ) receiving sugemalimab and XELOX as first-line treatment

In both studies,CS1001,either used as a monotherapy or in combination with chemotherapy,showed a well-tolerated safety profile

SUZHOU,China,Sept. 25,2020 -- CStone Pharmaceuticals (Suzhou) Co.,Ltd. ("CStone",HKSE: 2616) announced the updated results from two studies of its anti-PD-L1 monoclonal antibody sugemalimab (CS1001) at the 2020 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. These two studies are 1) CS1001-201 clinical trial,which is designed to evaluate sugemalimab as monotherapy in patients with R/R ENKTL,and 2) CS1001-101 study aiming to evaluate sugemalimab in combination with chemotherapy for the treatment of GC/GEJ. As an investigational drug developed by CStone,sugemalimab has shown promising efficacy and safety results in a variety of solid tumors and lymphomas as demonstrated by the current study results and those reported previously including the recent positive topline results from a pivotal phase III trial in patients with stage non-small cell lung cancer (NSCLC).

CS1001-201 Study

CS1001-201 is a single-arm,multi-center,phase II pivotal study designed to evaluate the efficacy and safety of sugemalimab as a monotherapy for the treatment of R/R ENKTL. The primary endpoint of this study is ORR as assessed by the Independent Radiology Review Committee (IRRC),and its secondary endpoints include investigator-assessed ORR,CR rate as assessed by IRRC and the investigator,median duration of response (mDoR),progression-free survival (PFS) and OS. The study also evaluated the safety,pharmacokinetics (PK) and immunogenicity of sugemalimab.

As of July 1,2020,a total of 43 patients were enrolled and received treatment. The demographic profile of patients at enrollment is similar to that of ENKTL patients: 74.4% of them had an ECOG score of 1; 72.1% had stage IV disease,and about a half (51.2%) have received second-line or above treatment

As a monotherapy,sugemalimab has demonstrated robust efficacy with a high CR rate and durable clinical benefits in terms of mDoR and OS,and a well-tolerated safety profile in R/R ENKTL patients

- The ORR of 38 evaluable patients was 44.7% with a CR rate as high as 31.6%. The mDoR was 16.8 months. Of all the 12 patients who achieved CR,11 are still in continuous remission

-The mOS of the 43 patients who received study drug treatment was 19.7 months,and 1-year OS rate was 55.5%

- The most commonly reported study drug-related adverse event was fever; drug-related adverse events (AEs) of grade 3 or above were observed in 6 patients (14.0%); 10 patients (23.3%) had immune-related AEs,most of which were grade 1; and 3 patients (7.0%) experienced severe adverse events (SAEs) related to the study drug

CS1001-101 Study

CS1001-101 is a phase I study to evaluate the safety,tolerability,PK and anti-tumor activity of sugemalimab in patients with advanced solid tumors or lymphomas. At the 2020 CSCO annual meeting,CStone presented the proof of concept (PoC) data of phase 1b cohort study designed to evaluate sugemalimab in combination with XELOX (capecitabine and oxaliplatin) as first-line treatment for locally advanced or metastatic GC/GEJ. The primary endpoint of this study is the preliminary anti-tumor efficacy of this combination therapy.

Sugemalimab in combination with XELOX as a first-line treatment has shown robust anti-tumor activity,as well as a benigh safety and tolerability profile in patients with advanced GC/GEJ. Preliminary biomarker analysis showed that the therapeutic effect of this combination therapy was potentially associated with the PD-L1 expression level.

As of February 19,among the 29 patients included in the efficacy analysis set,18 patients have achieved partial response (PR) and 6 patients have achieved stable disease (SD). The investigator-assessed ORR was 62.1%; the mDoR was 11.3 months; the mPFS was 8.3 months and the mOS was 17.0 months

26 patients in the efficacy analysis set have evaluable combined positive score (CPS) results. The analysis showed that the ORR of the subgroup with CPS ≥ 5 (19 patients) was 58%,the mDoR had not yet been reached,and that the mPFS was 13.3 months. In the subgroup with CPS <5 (7 patients),the reported ORR was 71%,the mDoR was 5.0 months,and the mPFS was 6.2 months

Dr. Jason Yang,Chief Medical Officer of CStone,said,"We are very pleased to see that sugemalimab,whether as a monotherapy or in combination with chemotherapy,has demonstrated promising anti-tumor activity and a benigh safety profile in R/R ENKTL and GC/GEJ patients. CS1001-201 is the world's first registrational clinical study designed to investigate the efficacy and safety of anti-PD-L1 monoclonal antibody in R/R ENKTL patients,and now we're extending it from China to the U.S. The promising efficacy results achieved for sugemalimab in combination with XELOX for the treatment of GC/GEJ patients continues to support our ongoing phase III study CS1001-303 (NCT03802591)."

About Sugemalimab

Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. Authorized by the U.S.-based Ligand Corporation,sugemalimab is developed by the OmniRat® transgenic animal platform,which can generate fully human antibodies in one stop. As a fully human,full-length anti-PD-L1 monoclonal antibody,sugemalimab mirrors the natural G-type immunoglobulin 4 (IgG4) human antibody,which can reduce the risk of immunogenicity and potential toxicities in patients,a unique advantage over similar drugs.

Sugemalimab has completed a Phase I dose-escalation study in China. During Phase 1a and 1b stages of the study,sugemalimab showed good antitumor activity and good tolerability in multiple tumor types.

Currently,sugemalimab is being investigated in a number of ongoing clinical trials. In addition to a Phase I bridging study in the U.S.,the clinical program in China includes one multi-arm Phase Ib study for several tumor types,one Phase II registrational study for lymphoma,and four Phase III registrational studies,respectively,for stage III/IV NSCLC,gastric cancer,and esophageal cancer. The phase III clinical trial of sugemalimab in patients with stage IV non-small cell lung cancer has reached its primary endpoint. CStone plans to submit a new drug application (NDA) to the National Medical Products Administration (NMPA) of China soon.

About CStone

CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015,CStone has assembled a world-class management team with extensive experience in innovative drug development,clinical research,and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently,5 late-stage candidates are at pivotal trials. With an experienced team,a rich pipeline,a robust clinical development-driven business model and substantial funding,CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

Forward-looking Statement

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law,we undertake no obligation to update or revise publicly any forward-looking statements,whether as a result of new information,future events or otherwise,after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article,statements of,or references to,our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.